Status:
TERMINATED
WIreless Monitoring and Financial Incentives for Uncontrolled HYpertension (WIFHY) Study
Lead Sponsor:
Duke-NUS Graduate Medical School
Collaborating Sponsors:
SingHealth Polyclinics
Conditions:
Hypertension
Eligibility:
All Genders
21-70 years
Phase:
NA
Brief Summary
Hypertension is a major risk factor for cardiovascular morbidity and mortality. Despite the risks of hypertension and availability of effective treatment, a substantial number of patients have uncontr...
Detailed Description
Hypertension is a major risk factor for cardiovascular morbidity and mortality. The ultimate goal of hypertension treatment is to lower blood pressure (BP) and thereby reduce cardiovascular risk. Desp...
Eligibility Criteria
Inclusion
- Known hypertensive patients on at least one anti-hypertensive medication
- SBP more than or equal to 140 mmHg or DBP more than or equal to 90 mmHg for patients without diabetes, SBP more than or equal to 140 mmHg or DBP more than or equal to 85 mmHg for patients with diabetes, as verified by the average of the last 2 of 3 BP readings taken, on the day of polyclinic visit, at 3 minutes interval using the Omron HEM-7130
- Aged between 21 to 70 years of age;
- Singaporean citizens or Permanent Residents;
- Able to converse in English or Mandarin;
- Has a compatible smartphone (iOS Versions 8.0 and higher or Android Versions 5.0 and higher) with data plan or regular Wi-Fi access
- Ability to perform self-monitoring of BP as assessed by the CRC
- Expecting to be a patient of Bedok or Marine Parade Polyclinics for the duration of the trial
Exclusion
- SBP equal or greater than 180mmHg or DBP equal or greater than 110mmHg, as verified by the average of the last 2 of 3 BP readings taken, on the day of polyclinic visit, at 3 minutes interval using the Omron HEM-7130
- pregnancy
- clinically unstable heart failure
- advanced kidney disease, i.e. eGFR \< 30 ml/min
- known liver disease
- Atrial Fibrillation
- underwent Double Mastectomy
- any other major debilitating disease or mental illness that precludes validity of informed consent or would result in the patient being unable to take their BP independently.
- started on angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin- receptor blockers (ARB) within the last 3 months
- on Warfarin or anti-coagulants (e.g. NOACs: Novel Oral Anticoagulants)
- known allergy to epoxy resin
- discharged from hospital within the last 3 months for complications related to hypertension
- newly referred to Specialist Outpatient Clinics (SOCs) or on follow-up for complications related to hypertension
- severe or overt macro albuminuria (urine ACR\>30mg/mmol or PCR\>0.5)
- confirmed glomerulonephritis
- living in a household where another member has been recruited into the trial
Key Trial Info
Start Date :
December 20 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 27 2019
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT03368417
Start Date
December 20 2017
End Date
January 27 2019
Last Update
March 11 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Marine Parade Polyclinic
Singapore, Singapore, 440080
2
Bedok Polyclinic
Singapore, Singapore, 469662